CZ20011394A3 - Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje - Google Patents

Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje

Info

Publication number
CZ20011394A3
CZ20011394A3 CZ20011394A CZ20011394A CZ20011394A3 CZ 20011394 A3 CZ20011394 A3 CZ 20011394A3 CZ 20011394 A CZ20011394 A CZ 20011394A CZ 20011394 A CZ20011394 A CZ 20011394A CZ 20011394 A3 CZ20011394 A3 CZ 20011394A3
Authority
CZ
Czechia
Prior art keywords
lower alkyl
heteroaryl
aryl
cycloalkyl
preparation
Prior art date
Application number
CZ20011394A
Other languages
English (en)
Inventor
William Harris
Christopher Huw Hill
Ian Edward David Smith
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314565&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ20011394(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823277.0A external-priority patent/GB9823277D0/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CZ20011394A3 publication Critical patent/CZ20011394A3/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Inorganic Insulating Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CZ20011394A 1998-10-23 1999-10-13 Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje CZ20011394A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9823277.0A GB9823277D0 (en) 1998-10-23 1998-10-23 Bicycle nitrogen heterocycles
GBGB9920044.6A GB9920044D0 (en) 1998-10-23 1999-08-24 Biciclic nitrogen heterocycles

Publications (1)

Publication Number Publication Date
CZ20011394A3 true CZ20011394A3 (cs) 2001-12-12

Family

ID=26314565

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011394A CZ20011394A3 (cs) 1998-10-23 1999-10-13 Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje

Country Status (25)

Country Link
US (1) US6150373A (cs)
EP (1) EP1123295B1 (cs)
JP (1) JP3593035B2 (cs)
CN (1) CN1150195C (cs)
AT (1) ATE277931T1 (cs)
AU (1) AU769989B2 (cs)
BR (1) BR9914677A (cs)
CA (1) CA2347474C (cs)
CZ (1) CZ20011394A3 (cs)
DE (1) DE69920732T2 (cs)
ES (1) ES2228123T3 (cs)
HK (1) HK1041483B (cs)
HR (1) HRP20010274A2 (cs)
HU (1) HUP0104199A3 (cs)
ID (1) ID28276A (cs)
MA (1) MA27678A1 (cs)
MY (1) MY126478A (cs)
NO (1) NO318802B1 (cs)
NZ (1) NZ510760A (cs)
PL (1) PL347432A1 (cs)
PT (1) PT1123295E (cs)
RU (1) RU2256662C2 (cs)
TR (1) TR200101102T2 (cs)
TW (1) TWI227235B (cs)
WO (1) WO2000024744A1 (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
SK17532000A3 (sk) 1998-05-26 2002-08-06 Warner-Lambert Company Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
JP2002528506A (ja) * 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−4−イルまたはピリミジン−4−イル置換ピラジン
HUP0203564A3 (en) * 1999-10-21 2004-07-28 Hoffmann La Roche Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them
BR0014973A (pt) * 1999-10-21 2002-07-16 Hoffmann La Roche Ag G Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
DE60015599T2 (de) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション CSBP/p38キナーゼ阻害剤としての3,4−ジヒドロ−(1H)−キナゾリン−2−オン化合物
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
AR030053A1 (es) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1333833B1 (en) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases
CA2441177A1 (en) 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
DE10235312A1 (de) * 2002-08-01 2004-02-12 Basf Ag Verfahren zur Herstellung von Aminoalkoxybenzylaminen und Aminoalkoxybenzonitrilen als Zwischenprodukte
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100497339C (zh) 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
ATE452121T1 (de) * 2003-04-23 2010-01-15 Japan Tobacco Inc Casr-antagonist
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
BRPI0514750A (pt) * 2004-08-31 2008-06-24 Hoffmann La Roche derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
CA2576818A1 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
DE602007001952D1 (de) 2006-01-31 2009-09-24 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
MX2015011514A (es) 2013-03-15 2016-08-11 Celgene Avilomics Res Inc Compuestos de heteroarilo y sus usos.
RS56924B9 (sr) 2013-04-19 2019-09-30 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3177295A4 (en) 2014-08-08 2018-06-13 Dana Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
US10308656B2 (en) * 2015-08-18 2019-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of Ku70/80 and uses thereof
CN110225914A (zh) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
RU2019129727A (ru) * 2017-02-28 2021-03-30 Зэ Дженерал Хоспитал Корпорэйшн Применения пиримидопиримидинонов в качестве ингибиторов sik
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
CA3087886A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
AR115296A1 (es) * 2018-12-27 2020-12-16 Agios Pharmaceuticals Inc Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220274991A1 (en) * 2019-07-16 2022-09-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
IL297714A (en) * 2020-04-28 2022-12-01 Iomx Therapeutics Ag Bicyclic kinase inhibitors and their uses
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
SK17532000A3 (sk) * 1998-05-26 2002-08-06 Warner-Lambert Company Prípadne substituované 3,4-dihydrogenované pyrimidíny, ich použitie a farmaceutické formulácie na ich báze

Also Published As

Publication number Publication date
ATE277931T1 (de) 2004-10-15
NO318802B1 (no) 2005-05-09
MA27678A1 (fr) 2006-01-02
NZ510760A (en) 2003-08-29
CN1324360A (zh) 2001-11-28
JP2002528455A (ja) 2002-09-03
TWI227235B (en) 2005-02-01
WO2000024744A1 (en) 2000-05-04
ES2228123T3 (es) 2005-04-01
DE69920732T2 (de) 2006-02-23
CA2347474A1 (en) 2000-05-04
CN1150195C (zh) 2004-05-19
HUP0104199A3 (en) 2002-12-28
NO20011929L (no) 2001-04-19
BR9914677A (pt) 2001-07-17
ID28276A (id) 2001-05-10
EP1123295B1 (en) 2004-09-29
MY126478A (en) 2006-10-31
HRP20010274A2 (en) 2002-06-30
NO20011929D0 (no) 2001-04-19
HK1041483B (zh) 2004-12-24
TR200101102T2 (tr) 2002-01-21
PT1123295E (pt) 2005-01-31
EP1123295A1 (en) 2001-08-16
RU2256662C2 (ru) 2005-07-20
HK1041483A1 (en) 2002-07-12
DE69920732D1 (de) 2004-11-04
AU769989B2 (en) 2004-02-12
JP3593035B2 (ja) 2004-11-24
CA2347474C (en) 2008-08-26
US6150373A (en) 2000-11-21
HUP0104199A2 (hu) 2002-04-29
PL347432A1 (en) 2002-04-08
AU1036300A (en) 2000-05-15

Similar Documents

Publication Publication Date Title
CZ20011394A3 (cs) Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
WO2005047290A3 (en) Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
NO995006L (no) Nye forbindelser
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
EP1206265A4 (en) SRC KINASE INHIBITOR COMPOUNDS
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU687909B2 (en) Protein kinase C inhibitors
BG103417A (en) Condensed pyrimidine bicyclic derivatives
YU29202A (sh) Alkilamino supstituisani biciklični azot heterocikli kao inhibitori p38 protein kinaze
WO2002090332A3 (en) Novel aeylheteroalkylaminε derivatives
SE9701304D0 (sv) Compounds
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
MY108482A (en) Compounds.
DE50211929D1 (en) Pyrimidinderivate
DE69217511T2 (de) Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel
YU29301A (sh) Biciklična azotna heterociklična jedinjenja
AU2001234314A1 (en) Novel phenylheteroalkylamine derivatives
NO995007L (no) Forbindelser
WO2003011210A3 (en) Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
ECSP993187A (es) Heterociclos biciclicos de nitrogeno